Radiopharmaceutical developer Navidea Biopharmaceuticals posted revenue decreases for its second quarter and six-month period (end-June 30).
Total revenue for the quarter was $260,000, compared with $542,000 in the second quarter of last year. Revenue for the first six months of 2019 was $302,000, compared with $819,000 in 2018. The company attributed the drop to a decrease in license revenue related to its NAV4694 beta-amyloid PET imaging agent for the diagnosis of early-onset Alzheimer's disease.
The company's net loss for the quarter increased to $2.7 million, up from $2.4 million in the same quarter of 2018. Its net loss for the six-month period was $5.1 million, compared with a net loss of $9.1 million last year.
